DE69921668D1 - Nachweis und bestimmung von stufen der coronaren arterienerkrankung - Google Patents

Nachweis und bestimmung von stufen der coronaren arterienerkrankung

Info

Publication number
DE69921668D1
DE69921668D1 DE69921668T DE69921668T DE69921668D1 DE 69921668 D1 DE69921668 D1 DE 69921668D1 DE 69921668 T DE69921668 T DE 69921668T DE 69921668 T DE69921668 T DE 69921668T DE 69921668 D1 DE69921668 D1 DE 69921668D1
Authority
DE
Germany
Prior art keywords
sample
clinically significant
patient
marker
testing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69921668T
Other languages
English (en)
Other versions
DE69921668T2 (de
Inventor
N Holvoet
J Collen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of DE69921668D1 publication Critical patent/DE69921668D1/de
Application granted granted Critical
Publication of DE69921668T2 publication Critical patent/DE69921668T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69921668T 1998-09-04 1999-08-31 Nachweis und bestimmung von stufen der coronaren arterienerkrankung Expired - Lifetime DE69921668T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US148158 1998-09-04
US09/148,158 US6309888B1 (en) 1998-09-04 1998-09-04 Detection and determination of the stages of coronary artery disease
PCT/IB1999/001596 WO2000014548A1 (en) 1998-09-04 1999-08-31 Detection and determination of the stages of coronary artery disease

Publications (2)

Publication Number Publication Date
DE69921668D1 true DE69921668D1 (de) 2004-12-09
DE69921668T2 DE69921668T2 (de) 2005-12-01

Family

ID=22524551

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921668T Expired - Lifetime DE69921668T2 (de) 1998-09-04 1999-08-31 Nachweis und bestimmung von stufen der coronaren arterienerkrankung

Country Status (8)

Country Link
US (4) US6309888B1 (de)
EP (2) EP1110092B1 (de)
AT (1) ATE281649T1 (de)
AU (1) AU5754699A (de)
CA (1) CA2342365C (de)
DE (1) DE69921668T2 (de)
ES (1) ES2228098T3 (de)
WO (1) WO2000014548A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20030077668A1 (en) * 1999-07-22 2003-04-24 Ikagaku Co., Ltd. Method for arteriosclerosis diagnosis
GB0001089D0 (en) * 2000-01-18 2000-03-08 Council Cent Lab Res Councils Lipoprotein assay
JP2003524187A (ja) * 2000-02-23 2003-08-12 ベッスト−テスト アンパーツゼルスカブ 体液、例えば尿におけるマーカーと血液凝固活性とを相互関連づけるための方法
US7250304B2 (en) * 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
US6596544B1 (en) * 2000-03-31 2003-07-22 The Regents Of The University Of California Functional assay of high-density lipoprotein
GB0027309D0 (en) * 2000-11-08 2000-12-27 Barts And The London Nat Healt Method of measuring measuring platlet activation
JP4162486B2 (ja) 2000-11-24 2008-10-08 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を用いる方法およびそのような酸化型リン脂質を含有する組成物
BE1013881A6 (fr) * 2000-12-21 2002-11-05 Univ Bruxelles Fractions de ldl oxydees, procede d'obtention et utilisation a but diagnostique ou therapeutique.
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040176914A1 (en) * 2001-04-13 2004-09-09 Biosite Incorporated Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040121350A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US20040126767A1 (en) * 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20050130321A1 (en) * 2001-04-23 2005-06-16 Nicholson Jeremy K. Methods for analysis of spectral data and their applications
EP1322957B1 (de) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
EP1419388B1 (de) * 2001-08-20 2009-10-07 Biosite Incorporated Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7476551B2 (en) * 2001-08-27 2009-01-13 The Board Of Trustees Of The University Of Arkansas Diagnosing atherosclerosis risk by measuring carbamylated low density lipoprotein levels
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
EP2386864A1 (de) * 2002-10-09 2011-11-16 DMI Biosciences, Inc. Diagnose und Uberwachung von Ischämie
AU2003284065A1 (en) * 2002-10-11 2005-05-05 Chien-Min Sung Carbonaceous heat spreader and associated methods
ES2739463T3 (es) * 2003-03-27 2020-01-31 Childrens Hospital Med Ct Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales
US7095245B2 (en) * 2003-11-14 2006-08-22 Intel Corporation Internal voltage reference for memory interface
WO2005064307A2 (en) * 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2876453B1 (fr) * 2004-10-11 2007-01-12 Biomerieux Sa Procede de diagnostic d'exclusion in vitro des syndromes coronariens aigus
SI1831699T1 (sl) * 2004-12-20 2010-03-31 Antibodyshop As Določanje nevtrofilnega lipokalina asociiranega z želatinazo ngal kot diagnostičnega markerja za ledvične bolezni
CA2599731A1 (en) * 2005-03-03 2006-09-08 Dmi Biosciences, Inc. Quantification of proteins
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
US7972794B2 (en) * 2006-07-18 2011-07-05 Quest Diagnostics Investments Incorporated Oxidized apoA-I determination by mass spectrometry
EP2602624A1 (de) * 2006-08-07 2013-06-12 Antibodyshop A/S Diagnostischer Test zum Ausschliessen einer signifikanten Nierenverletzung
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
US7776605B2 (en) * 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
CA2667012A1 (en) * 2006-10-26 2008-05-02 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
MX2009006744A (es) * 2006-12-22 2009-06-30 Abbott Lab Panel de padecimiento cardiovascular autoinmune y metodos de utilizacion del mismo.
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US7521248B2 (en) * 2007-04-20 2009-04-21 Atherotech, Inc. Apo B measurement system and method
CN101910845A (zh) * 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
EP3093663B1 (de) 2008-04-18 2018-06-13 Critical Care Diagnostics, Inc. Vorhersage des risikos für schwere unerwünschte herzereignisse
US20090327335A1 (en) * 2008-06-30 2009-12-31 General Electric Company Systems and Methods For Generating Vendor-Independent Computer-Aided Diagnosis Markers
WO2010009269A2 (en) * 2008-07-15 2010-01-21 Piedmont Healthcare, Inc. Method for coronary artery disease risk assessment
CN102099470B (zh) 2008-08-15 2014-11-12 藤仓化成株式会社 用于诊断动脉硬化的多肽标记、用该标记等检测动脉硬化的方法以及用于诊断动脉硬化的试剂盒
MX343328B (es) 2009-10-26 2016-11-01 Nestec Sa Analisis para la deteccion de farmacos anti-tnf y anticuerpos.
EP2499489B1 (de) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risikofaktoren und vorhersage von myokardinfarkt
JP5914326B2 (ja) * 2010-03-31 2016-05-11 積水メディカル株式会社 イムノクロマトグラフィーを利用した測定方法、イムノクロマトグラフィー用テストストリップ及びイムノクロマトグラフィー用測定試薬キット
DK2577316T3 (en) * 2010-05-31 2017-05-08 Univ Hospital Of Basel Procedure for testing for lower respiratory tract infections or inflammation
BR112013009376A2 (pt) 2010-10-18 2016-07-26 Nestec Sa métodos para determinar isótipos de anticorpos antifármacos
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
EP2753935A1 (de) * 2011-09-07 2014-07-16 Genway Biotech, Inc. Diagnostischer assay zur vorhersage von kardiovaskulärem risiko
WO2013045500A1 (en) * 2011-09-26 2013-04-04 Universite Pierre Et Marie Curie (Paris 6) Method for determining a predictive function for discriminating patients according to their disease activity status
US20130295685A1 (en) * 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
CN102680710B (zh) * 2012-05-22 2014-06-11 成都华神生物技术有限责任公司 一种人氧化低密度脂蛋白的酶联免疫检测试剂盒及使用方法、用途
AU2013305829A1 (en) 2012-08-21 2015-03-05 Critical Care Diagnostics, Inc. Multimarker risk stratification
EP2730923A1 (de) * 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP- und cTnT-basierte Therapieanleitung bei Herzversagen
US20150260631A1 (en) * 2014-03-17 2015-09-17 Health Diagnostic Laboratory, Inc. System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions
SG11201704200SA (en) 2014-12-05 2017-06-29 Nestec Sa Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
CN104914255A (zh) * 2015-05-21 2015-09-16 北京协和洛克生物技术有限责任公司 一种检测样本中氧化低密度脂蛋白浓度的试剂盒及其制备方法
US11226343B2 (en) * 2016-04-08 2022-01-18 Biothelis Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
WO2017210360A1 (en) 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN114533264A (zh) * 2022-01-25 2022-05-27 中山大学孙逸仙纪念医院 一种无症状性冠脉疾病的预测模型训练方法、装置及系统

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
DE68922126T2 (de) 1988-01-19 1995-11-09 Pasteur Institut Immunometrisches Verfahren zum Nachweis von Lipoprotein-Teilchen, anti-Lp(a) Monoklonale Antikörper und ihre Anwendung zur Diagnose von Atherosklerose.
US5120834A (en) 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5223410A (en) 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
US5453359A (en) 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5046499A (en) 1988-06-13 1991-09-10 Centocor, Inc. Method for myocardial infarct risk assessment
US5024829A (en) 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
US5026537A (en) 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US5710008B1 (en) * 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
JP3115587B2 (ja) 1990-11-07 2000-12-11 第一化学薬品株式会社 モノクローナル抗体及びマロンジアルデヒド化低比重リポタンパクの測定法
EP0590200A1 (de) 1992-10-02 1994-04-06 E.R. SQUIBB & SONS, INC. Gerät und Verfahren zur Sichtbarmachung von kardiovaskulären Risikofaktoren
US5380667A (en) 1992-10-30 1995-01-10 The United States Of America As Represented By The Secretary Of The Air Force Serum bilirubin and liver function tests as risk predictors for coronary artery disease
US5362649A (en) 1993-02-16 1994-11-08 The United States Of America As Represented By The Secretary Of The Air Force Method for concentration based analysis of lipid fatty acids and its use in determining the likelihood that a patient is at risk for coronary artery disease
WO1994023302A1 (en) 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma
EP0728019A4 (de) 1993-11-08 1999-07-07 Peptide Delivery Systems Pty L Maskierte diagnostikpräparate und verfahren für ihre verwendung
US5487892A (en) 1994-02-24 1996-01-30 American Biogenetic Sciences, Inc. Method for treating thrombotic disease using a fibrin specific monoclonal antibody
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
JPH095323A (ja) 1995-04-21 1997-01-10 Wako Pure Chem Ind Ltd 酸化低比重リポ蛋白質の測定方法
JP3365885B2 (ja) 1995-04-28 2003-01-14 株式会社ベッセルリサーチ・ラボラトリー ヒト酸化リポタンパク質の測定法
US5690103A (en) 1996-06-20 1997-11-25 Groth; Torgny Lars Detection/exclusion of acute myocardial infarction using neural network analysis of measurements of biochemical markers
US5731208A (en) 1996-09-09 1998-03-24 Washington University Method of detecting conditions indicative of atherosclerosis
CA2285091A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
ATE385575T1 (de) 1997-06-20 2008-02-15 Leuven Res & Dev Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
EP1386165B1 (de) 2000-12-14 2011-11-02 The Brigham And Women's Hospital, Inc. Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
JP2005515407A (ja) 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）

Also Published As

Publication number Publication date
ATE281649T1 (de) 2004-11-15
EP1503213A2 (de) 2005-02-02
ES2228098T3 (es) 2005-04-01
US6309888B1 (en) 2001-10-30
CA2342365A1 (en) 2000-03-16
US20010049112A1 (en) 2001-12-06
WO2000014548A1 (en) 2000-03-16
EP1503213A3 (de) 2005-07-13
DE69921668T2 (de) 2005-12-01
CA2342365C (en) 2008-05-06
US20070190586A1 (en) 2007-08-16
EP1110092A1 (de) 2001-06-27
US7604952B2 (en) 2009-10-20
EP1110092B1 (de) 2004-11-03
US20030013127A1 (en) 2003-01-16
US7166469B2 (en) 2007-01-23
AU5754699A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
DE69921668D1 (de) Nachweis und bestimmung von stufen der coronaren arterienerkrankung
Johnson et al. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review
Higenbottam et al. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension
Bruinstroop et al. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis
NO994365L (no) Forutsigelse av koronararterie-sykdom
DE60314042D1 (de) Vorrichtungen und Methoden zur Bestimmung von Konzentrationen von Analyten
ATE546734T1 (de) Risikomarker für eine herzkreislaufkrankheit
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
ATE394658T1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
ATE319105T1 (de) Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2
MY133942A (en) Reagent test strip for analyte determination having hemolyzing agent
NO160746C (no) Fremgangsmaate for paavisning av okkult blod i fecesproever.
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
NO954897L (no) Fremgangsmåte for å bestemme et individs inflammasjonsindeks fra hele blodfibrinogen og hematokrit eller hemoglobinmålinger
EP1221620A3 (de) Verfahren zum Ausführen einer Bestimmung der "activated clotting time" mit geringer Empfindlichkeit gegenüber die Anwesenheit des Aprotinins sowie zur Ermittlung der Aprotinin-Empfindlichkeit
ATE100150T1 (de) Verfahren zur bestimmung von physiologisch wirksamen substanzen.
Katzel et al. Risk factors for exercise-induced silent myocardial ischemia in healthy volunteers
Bergelson et al. Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplasty
DE60133510D1 (de) Automatisches Verfahren zur quantitativen Bestimmung und Überwachung von exogenem Hämoglobin in Vollblut, Blutplasma und Blutserum
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
WO2000026251A3 (en) A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
AU6679501A (en) A method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
ATE159102T1 (de) Serum antioxydationsmittel zur voraussage von adult respiratory distress syndrome
ATE242487T1 (de) Verfahren zur bestimmung von schilddrüsen- autoantikörpern
IL143639A0 (en) Method for determining the activity of a substance using a functional test in vitro

Legal Events

Date Code Title Description
8364 No opposition during term of opposition